DRTS
—
—
Loading…
—
—
MASTER
—
—
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
ESEN Output Unavailable — DRTS
Generated: 2026-10-22T02:56:46Z
> build_news_intel failed: BadRequestError
> Error code: 400 - {'type': 'error', 'error': {'type': 'invalid_request_error', 'message': 'Your credit balance is too low to access the Anthropic API. Please go to Plans & Billing to upgrade or purchase credits.'}, 'request_id': 'req_011CgGXMBQGbD7RCeYb73YpR'}
SNAPSHOT
Ticker
DRTS
Company
Alpha Tau Medical Ltd
Sector | Industry
Health Care | Medical Devices
Market Cap
$1,217.0M
Current Price
$13.16 +2.02%
52-Week Range
$3.43 — $15.79
52-Week Return
+212.59%
Beta
1.27 (High Volatility)
EARNINGS MOMENTUM
Last 4 quarters EPS actual vs estimate, revenue growth, guidance trends
| Metric | Value | Status |
|---|---|---|
| EPS (TTM) | -$0.66 | Unprofitable |
| EPS Growth YoY | Data not disclosed | Limited Visibility |
| Revenue Growth YoY | Data not disclosed | Limited Visibility |
| Forward P/E | Not meaningful (unprofitable) | N/A |
| Earnings Date | Not disclosed | Data Gap |
Earnings Momentum Score: 6/10
Early-stage medical device company in negative earnings. Stock rallied 212.6% in 52 weeks, indicating strong investor optimism around clinical pipeline or commercialization progress. However, persistent operating losses and absent forward earnings guidance constrain near-term momentum visibility. Revenue and earnings trajectory data required for full assessment.
Early-stage medical device company in negative earnings. Stock rallied 212.6% in 52 weeks, indicating strong investor optimism around clinical pipeline or commercialization progress. However, persistent operating losses and absent forward earnings guidance constrain near-term momentum visibility. Revenue and earnings trajectory data required for full assessment.
PROFITABILITY & QUALITY
Operating margins, returns on capital, cash flow trends
| Metric | Value | Assessment |
|---|---|---|
| Gross Margin | Data not disclosed | Constrained Coverage |
| Operating Margin | Data not disclosed | Constrained Coverage |
| Net Profit Margin | Negative (EPS -$0.66) | Pre-Profitability |
| ROE / ROIC | Data not disclosed | Constrained Coverage |
| Free Cash Flow (TTM) | Data not disclosed | Constrained Coverage |
Quality Score: 5/10
Alpha Tau Medical is a pre-revenue or early-revenue stage medical device company. Negative EPS (-$0.66) indicates R&D burn and limited commercialization at present. Absence of disclosed margin, cash flow, and return metrics typical for companies in clinical/commercial transition. Quality assessment constrained by lack of detailed financial reporting. Professional institutional investors require full income statement and cash flow disclosure before confidence in operational quality.
Alpha Tau Medical is a pre-revenue or early-revenue stage medical device company. Negative EPS (-$0.66) indicates R&D burn and limited commercialization at present. Absence of disclosed margin, cash flow, and return metrics typical for companies in clinical/commercial transition. Quality assessment constrained by lack of detailed financial reporting. Professional institutional investors require full income statement and cash flow disclosure before confidence in operational quality.
BALANCE SHEET HEALTH
Liquidity, leverage, and solvency profile
| Metric | Value | Risk Level |
|---|---|---|
| Cash & Equivalents | Data not disclosed | Unknown |
| Total Debt | Data not disclosed | Unknown |
| Net Debt / EBITDA | Not calculable (negative EBITDA likely) | N/A |
| Current Ratio | Data not disclosed | Unknown |
| Share Dilution Risk | Likely elevated (biotech burn model) | Medium-High |
Balance Sheet Risk: MEDIUM-HIGH
Early-stage medical device company with operating losses typically requires ongoing capital raises. Balance sheet details not disclosed in current reporting. Shareholders should expect future dilution through equity or debt financing to fund R&D and commercialization. Liquidity runway and debt position require direct company disclosure for full credit assessment. Without balance sheet transparency, risk profile cannot be fully modeled.
Early-stage medical device company with operating losses typically requires ongoing capital raises. Balance sheet details not disclosed in current reporting. Shareholders should expect future dilution through equity or debt financing to fund R&D and commercialization. Liquidity runway and debt position require direct company disclosure for full credit assessment. Without balance sheet transparency, risk profile cannot be fully modeled.
VALUATION ANALYSIS
Price multiples vs. sector benchmarks and intrinsic value indicators
| Metric | DRTS | Assessment |
|---|---|---|
| Trailing P/E | Not meaningful (negative earnings) | N/A |
| Forward P/E | Not meaningful (not disclosed) | N/A |
| PEG Ratio | Not calculable | N/A |
| Price / Sales | Not calculable (revenue not disclosed) | Constrained |
| EV / EBITDA | Not meaningful (negative EBITDA likely) | N/A |
| Market Cap | $1,217.0M | Moderate-cap biotech |
Valuation Status: SPECULATIVE / PHASE-DEPENDENT
Traditional valuation multiples are not applicable for unprofitable medical device companies. Stock valuation is purely driven by clinical trial progress, regulatory pathway expectations, and market sentiment around pipeline. Market cap of $1.2B implies investor conviction in technology/market opportunity, but absent revenue, earnings, and detailed pipeline disclosure, fundamental valuation cannot be performed. Price reflects investor beta and conviction in Alpha Tau's alpha-emitting radiotherapy platform, not cash flow fundamentals.
Traditional valuation multiples are not applicable for unprofitable medical device companies. Stock valuation is purely driven by clinical trial progress, regulatory pathway expectations, and market sentiment around pipeline. Market cap of $1.2B implies investor conviction in technology/market opportunity, but absent revenue, earnings, and detailed pipeline disclosure, fundamental valuation cannot be performed. Price reflects investor beta and conviction in Alpha Tau's alpha-emitting radiotherapy platform, not cash flow fundamentals.
ANALYST TARGETS & SENTIMENT
Consensus ratings, price targets, upside/downside potential
| Metric | Value | Status |
|---|---|---|
| Consensus Rating | Not disclosed | Data Gap |
| Mean Price Target | Not disclosed | Data Gap |
| High Price Target | Not disclosed | Data Gap |
| Low Price Target | Not disclosed | Data Gap |
| Implied Upside / Downside | Not calculable | Data Gap |
Wall Street Sentiment: LIMITED COVERAGE
Analyst target price and consensus rating data not currently disclosed in live reporting. Alpha Tau Medical Ltd is a micro/small-cap Israeli biotech company trading on NASDAQ. Coverage may be limited to specialized biotech research teams. Institutional investors should source analyst research directly from specialized biotech platforms (e.g., Cowen, Needham, Oppenheimer) for clinical trial stage assessments and price targets. Absence of consensus targets typical for companies with limited liquidity and early-stage clinical programs.
Analyst target price and consensus rating data not currently disclosed in live reporting. Alpha Tau Medical Ltd is a micro/small-cap Israeli biotech company trading on NASDAQ. Coverage may be limited to specialized biotech research teams. Institutional investors should source analyst research directly from specialized biotech platforms (e.g., Cowen, Needham, Oppenheimer) for clinical trial stage assessments and price targets. Absence of consensus targets typical for companies with limited liquidity and early-stage clinical programs.
INSTITUTIONAL & RISK CHECK
Ownership trends, insider activity, short interest, regulatory and execution risks
| Risk Factor | Status | Assessment |
|---|---|---|
| Institutional Ownership % | Data not disclosed | Unknown |
| Insider Activity | Data not disclosed | Unknown |
| Short Interest % | Data not disclosed | Unknown |
| Clinical Trial Risk | Early-stage (likely Phase 1-2) | HIGH |
| Regulatory Approval Path | Data not disclosed | Unknown |
| Capital Requirement Risk | High (pre-revenue burn) | HIGH |
| Technology Risk | Alpha-emitting radiotherapy (proprietary) | MEDIUM |
Overall Risk Level: HIGH
Key Risk Factors: (1) Pre-revenue / minimal revenue stage with negative earnings. (2) Typical biotech dilution risk from ongoing capital raises. (3) Clinical trial execution risk for early-stage proprietary radiotherapy platform. (4) Regulatory approval uncertainty for novel therapeutic modality. (5) Limited institutional research coverage and analyst consensus. (6) High stock beta (1.27) reflects volatility typical of speculative biotech. (7) Liquidity runway and financing needs not publicly disclosed. Suitable for high-risk/high-conviction venture-stage biotech investors only.
Key Risk Factors: (1) Pre-revenue / minimal revenue stage with negative earnings. (2) Typical biotech dilution risk from ongoing capital raises. (3) Clinical trial execution risk for early-stage proprietary radiotherapy platform. (4) Regulatory approval uncertainty for novel therapeutic modality. (5) Limited institutional research coverage and analyst consensus. (6) High stock beta (1.27) reflects volatility typical of speculative biotech. (7) Liquidity runway and financing needs not publicly disclosed. Suitable for high-risk/high-conviction venture-stage biotech investors only.
FINAL ESEN VERDICT
23
Fundamental Score
Conviction Level
MODERATE-LOW — Speculative conviction appropriate only for biotech-focused venture investors with deep clinical/regulatory expertise. Absence of historical revenue, earnings, and detailed pipeline data severely limits institutional fundamental analysis.
Time Horizon Assessment
| Short Term (1-3M) | Momentum-driven; stock rallied 212.6% YTD. Near-term catalysts likely clinical/regulatory updates. High volatility expected. |
| Medium Term (6-12M) | Dependent on clinical trial progress, safety/efficacy readouts, partnerships. Revenue inflection inflection or financing event probable. |
| Long Term (2Y+) | Regulatory approval pathway and commercial market adoption critical. Success requires sustained execution across clinical, regulatory, and manufacturing. |
Summary Assessment
- Momentum Strong (+212.6% YTD): Market pricing in meaningful clinical/commercial optionality for Alpha Tau's alpha-emitting radiotherapy platform.
- Fundamentals Opaque: Unprofitable (EPS -$0.66), no revenue disclosure, absent balance sheet transparency. Traditional valuation inapplicable.
- Risk/Reward Asymmetric: Suitable for venture-stage biotech investors only; mainstream institutional investors should await clinical milestones, revenue inflection, or profitability path visibility.
- Data Gaps Limit Scoring: Radar scores reflect high uncertainty. Full financial statements, clinical trial data, and management guidance required for institutional-grade analysis.
- Recommendation: SPECULATIVE BUY for biotech specialists; HOLD/AVOID for core equity allocators until: (A) Clinical trial efficacy confirmed, (B) Revenue ramp initiated, (C) Path to profitability clarified, (D) Full balance sheet disclosure provided.
AI STOCK INSIGHT
DRTS Stock Analysis & Forecast
Is DRTS a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
DRTS Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, DRTS shows balanced risk-reward characteristics.
Should You Buy DRTS Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in DRTS.